Study protocol for SKIPMDD: subcutaneous ketamine infusion in palliative care patients with advanced life limiting illnesses for major depressive disorder (phase II pilot feasibility study)

INTRODUCTION: Major depressive disorder (MDD) in people with advanced life-limiting illnesses can have significant impact on the quality-of-life of those affected. The management of MDD in the palliative care setting can be challenging as typical antidepressants may not work in time nor be tolerated...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Wei, Sheehan, Caitlin, Chye, Richard, Chang, Sungwon, Loo, Colleen, Draper, Brian, Agar, Meera, Currow, David C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Palliative Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240583/
https://www.ncbi.nlm.nih.gov/pubmed/34183351
http://dx.doi.org/10.1136/bmjopen-2021-052312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240583/
https://www.ncbi.nlm.nih.gov/pubmed/34183351
http://dx.doi.org/10.1136/bmjopen-2021-052312

Ejemplares similares